secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001193125-25-304559
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology completes first U.S. commercial sale of KOMZIFTI, triggering $135M milestone payment from Kyowa Kirin
--------------------------------------------------------------------------------

- First commercial sale of KOMZIFTI (ziftomenib) completed on December 2, 2025.
- Milestone triggers $135M payment from Kyowa Kirin, expected before year-end 2025.
- KOMZIFTI received FDA approval on November 13, 2025.
- Payment is under the existing collaboration and license agreement with Kyowa Kirin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525304559/0001193125-25-304559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525304559/d75668d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-304559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer